Oncology diagnostics is the highest-growth and highest-value application segment in IVD, at the intersection of molecular diagnostics, immunoassay, and digital pathology. The cancer diagnostics market is projected to reach $10 billion by 2026. Liquid biopsy — detecting circulating tumor DNA, circulating free RNA, and other cancer biomarkers in blood — is creating an entirely new segment with the potential to enable multi-cancer early detection at population scale. Labcorp agreed to acquire oncology and clinical-testing assets from BioReference Health in March 2025. In May 2023, Freenome acquired Oncimmune, developing a CE-IVD lung cancer blood test. Companion diagnostics — IVD tests required for the prescription of targeted therapies — represent a structurally growing segment as precision oncology drug approvals accelerate.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Oncology IVD Market Size and Forecast 2025-2030 by Application and Technology
• Companion Diagnostics — FDA/EMA Co-Development, Market Size, and Leading CDx Suppliers
• Liquid Biopsy — ctDNA, cfRNA, CTCs, and Multi-Cancer Early Detection
• Somatic Mutation Testing — NGS Panels, PCR-Based Testing, and Tumor Profiling
• Germline Hereditary Cancer Testing — BRCA, Lynch Syndrome, and Expanded Panels
• Digital Pathology and Anatomic Pathology — Tissue Diagnostics and AI-Powered Image Analysis
• Tumor Markers and Immunoassay — PSA, CA-125, CEA, and Novel Biomarkers
• Competitive Landscape — Roche, Illumina, Guardant, Exact Sciences, Foundation Medicine
• Investment and Partnership Opportunities